More Than a New Copper Top.….

The standard of care for wound irrigation has evolved. ViaCLYR® with Clyrasept® is changing how we approach antimicrobial wound management.

Powered by gentle but effective oxidative chemistry, it delivers superior performance without the drawbacks of legacy solutions:

• No Rinse Required: Non-toxic and non-irritating, saving critical clinical time.

• Tissue Friendly: Cleanses and treats wounds without harming healthy tissue; does not sting or stain.

• Advanced Care: Superior, extended wound odor control with no alcohol, steroids, or antibiotics.

• Ready to Use: No mixing or dilution required for immediate, effective application.

The future of wound irrigation is here….

#WoundCare #MedTech #HealthcareInnovation #ViaCLYR #Clyrasept #AdvancedWoundCare

$BLGO BioLargo’s Q2 2026 10-Q is out. Not pretty, but at least revenues are growing again—from $1.12M in Q1 to $1.25M in Q2, while gross profit improved from $458K to $675K...
So the downtrend is over!
Also for financing the launch mode on many different different endeavors that we only faced 2,5 % dilution so far this year is pretty impressive.

https://www.sec.gov/Archives/edgar/data/880242/000143774926028023/blgo20260801\_10q.htm

Now it is key to see continued Clyra sales growth, broader AEC adoption, and—hopefully—the launch of BioLargo’s own consumer odor-control product soon.

Many multiple X share price growth could be triggered from multiple directions.

BE greedy when others are fearful….
I’ll keep adding - beating the dilution by far

Good info.

The Final Deadline is Approaching August 14th.
The Evolution Mallorca International Film Festival is looking for the best projects in many categories.

For 50% off at filmfreeway.

Code: iamlatemallorca

BioLargo Inc. (BLGO:OTCQX) announces the processing of more than 2 million gallons of PFAS-contaminated water using its patented Aqueous Electrostatic Concentrator (AEC) technology. Find out why one technical analyst likes BLGO's business model.

BIOLARGO - BLGO announced that its
patented Aqueous Electrostatic Concentrator (AEC) has processed more than 2 million gallons of PFAS-contaminated water after more than six months of continuous commercial operation at the municipal drinking water facility in Lake Stockholm, New Jersey, according to an August 3 release.
The installation, which began operating in January 2026, now serves as a commercial demonstration site where prospective customers can evaluate the technology firsthand.
Since its installation, the AEC system has consistently reduced PFAS concentrations in Lake Stockholm's drinking water to levels below all applicable New Jersey Department of Environmental Protection (NJDEP) standards and U.S. Environmental Protection Agency maximum contaminant limits. BioLargo said the system's proprietary collection process also generates substantially less contaminated waste than traditional carbon filtration systems, helping lower the municipality's hazardous waste disposal costs.
The company noted that both the NJDEP and the U.S. EPA continue to oversee and evaluate the AEC system through a 12-month monitoring program designed to verify that the technology consistently meets or exceeds regulatory standards.

"With our system running for more than six months now, having removed PFAS chemicals from over 2 million gallons of drinking water, the Lake Stockholm installation gives our potential customers and their engineers a working installation to confirm both AEC's effectiveness and operational cost savings. The question is no longer 'does it work,' but rather 'where and how quickly' the AEC can be deployed next," said BioLargo President and Chief Executive Officer Dennis P. Calvert.

What Are 'Forever Chemicals'?
Commonly referred to as "forever chemicals," PFAS (per- and polyfluoroalkyl substances) are built around one of the strongest bonds in organic chemistry, the carbon-fluorine bond. According to the release, engineers prized it for making non-stick pans, waterproof jackets, and grease-resistant food wrappers.
"But that same indestructibility means these chemicals never break down — not in a landfill, not in a river, and not inside human beings," the company said in the release. "Once PFAS enter your bloodstream, they lodge in organs, blood, and bones. Some of these compounds can persist in the human body for years per exposure, meaning every glass of contaminated water, every use of certain consumer products, adds to a body burden that never fully resets."

The company said research has linked PFAS exposure to a range of health concerns, including certain cancers, weakened immune function, thyroid disorders, and developmental harm in children. Because PFAS contamination is widespread and detectable in the blood of most Americans who have been tested, BioLargo said the issue extends far beyond communities located near chemical manufacturing facilities. It also cited an August 2024 estimate from the American Water Works Association that projected utilities would spend between US$385,000 and US$500,000 annually per drinking water entry point to comply with U.S. EPA regulations governing maximum allowable PFAS levels.

BioLargo said conventional treatment methods, including granular activated carbon and ion exchange systems, often have difficulty capturing short-chain PFAS compounds, require ongoing replacement of filter media, and generate significant volumes of contaminated spent media and brine that must be disposed of through hazardous waste landfills or incineration, which can create additional environmental concerns.

By comparison, BioLargo said its AEC technology eliminates the need for granular activated carbon or single-use ion exchange resins while producing only a small volume of concentrated residual waste. At the Lake Stockholm facility, BioLargo said the system has lowered operating costs compared with what the municipality would have incurred using conventional granular activated carbon treatment.

"Utility engineers and regulators want to see a real municipal installation under third-party monitoring before they move to adopt a new technology. Lake Stockholm gives us that for the AEC," said BioLargo Equipment Solutions & Technologies President Tonya Chandler.
Beyond municipal drinking water, BioLargo said it believes the Lake Stockholm project highlights broader commercial opportunities for the AEC technology in treating industrial wastewater, landfill leachate, and contaminated groundwater. The company said it continues to conduct bench-scale pilot projects with prospective municipal and industrial customers while expanding commercialization efforts, including its recently announced memorandum of understanding with global water treatment company Aquatech.
"Lake Stockholm is the launch pad for our strategy with Aquatech. Together we intend to pair the AEC with their PFAS treatment and destruction capabilities and extend it beyond municipal drinking water to more of the PFAS challenges customers face," said Calvert.
BioLargo added that testing at the Lake Stockholm facility will continue under the U.S. EPA monitoring program, and the company plans to release additional third-party performance data as it becomes available.

Wound Care Platform's Flagship Product Shows Promise, Co. Says
Another BioLargo company, Clyra Medical Technologies, is advancing a wound care platform centered on its patented Copper-Iodine Complex Solution (CICS), which it markets under the Clyrasept brand. Its flagship product, ViaCLYR, has received FDA 510(k) clearance as a wound irrigation solution for cleansing, irrigating, and debriding dermal wounds and burns, as well as moistening and lubricating absorbent wound dressings. The clearance covers a broad range of wound types, including burns, pressure ulcers, diabetic and stasis ulcers, post-surgical wounds, and abrasions.
The company said ViaCLYR differs from conventional antiseptics through what it describes as a "chemistry on demand" approach. Rather than releasing a high concentration of antiseptic immediately, the solution maintains a reservoir of approximately 250 parts per million of iodine potential and gradually releases small amounts of free iodine as microbes are encountered. According to Clyra's in vitro technical data, the solution continued to neutralize repeated bacterial challenges introduced over a 72-hour period without replenishment, supporting the antimicrobial persistence of the preservative in solution.

Laboratory testing cited by the company found that ViaCLYR neutralized 19 bacterial and fungal organisms, including antibiotic-resistant pathogens such as MRSA, VRE, Acinetobacter baumannii, and Candida auris, within one minute. Clyra also said comparative cytotoxicity testing showed the product did not damage healthy dermal cells, unlike several commonly used wound care antiseptics, including Dakin's solution, chlorhexidine gluconate, hydrogen peroxide, and povidone iodine.
The company emphasized that these laboratory findings relate to the preservative's antimicrobial activity in vitro and are not included in ViaCLYR's FDA-cleared indications. The FDA clearance does not authorize claims that the product eliminates pathogens in wounds or treats or prevents infection. Clyra said it believes the combination of broad antimicrobial activity, prolonged performance, lack of observed cytotoxicity, no reported resistance, and no requirement for rinsing addresses a longstanding need in wound care.

Clyra Chief Executive Officer Steve Harrison described the product's potential advantages by recalling a discussion with a prominent burn surgeon, who told him a competing product "lasts about two minutes," requiring more frequent dressing changes. Harrison said, "More labor, more cost, more time, more pain and suffering to make (the) product work. We're not asking any of that... a product that doesn't need to generate more dressing changes, more suffering, more pain, more crying, more bleeding, and more cost and expense."
According to Harrison, the product's efficiency could also help hospitals operating under financial constraints by reducing the burden on clinical staff and allowing physicians and nurses to care for more patients. He added that Clyra is currently negotiating pricing agreements with several large U.S. health systems, supported by strong interest from physicians.

Analyst Likes Company's Strategy
Technical Analyst John Newell of John Newell & Associates highlighted BioLargo's healthcare progress through its majority-owned subsidiary, Clyra Medical Technologies, in a March 11 report for Streetwise Reports. Newell said BioLargo has followed a methodical approach by extensively validating its proprietary technologies through scientific research before partnering with established organizations to broaden commercialization. He noted that the company's technology portfolio extends across water treatment, environmental cleanup, air quality, energy storage, and medical technologies.

According to Newell, Clyra ranks among BioLargo's most significant healthcare assets because its copper-iodine antimicrobial technology provides up to 72 hours of antimicrobial activity while remaining non-cytotoxic, making it suitable for wound care and infection control applications. He also pointed to ViaCLYR's FDA 510(k) clearance, which enables distribution through established medical device sales channels, and said the platform is supported by about 40 issued and pending patents covering products in liquid, powder, hydrogel, and antimicrobial dressing formats.

Based on the prospects for BioLargo's various technology platforms, Newell assigned the company a Speculative Buy rating. He said BioLargo's measured commercialization strategy, combined with its focus on strategic partnerships, positions the company to capitalize on increasing demand for advanced healthcare technologies and sustainable energy storage products.
In a May 18 report, Oak Ridge Financial Analyst Richard Ryan characterized BioLargo's operating strategy as a "hub and spoke format invent/acquire a product, prototype/prove it out, partner with necessary third parties, and commercialize." Ryan reiterated his Buy rating, saying BioLargo's practice of commercializing technologies through separate operating subsidiaries diversifies risk while allowing the company to maintain meaningful ownership stakes in businesses targeting multiple high-growth markets.

The Catalyst: Millions Could Be Affected?
The Environmental Working Group (EWG) said its latest PFAS contamination map identifies 9,728 confirmed sites with detectable levels of the so-called "forever chemicals" across all 50 states, the District of Columbia and four U.S. territories. The nonprofit said updated data from the U.S. Environmental Protection Agency found PFAS in 3,539 public water systems, bringing the total number of known contaminated locations to 9,728. According to EWG, the findings indicate that about 176 million people live in communities where drinking water has tested positive for PFAS, although the group said the true extent of contamination is likely greater because current federal reporting thresholds are higher than those used in earlier research.

According to Grand View Research in June, the global PFAS treatment market size was estimated at US$2.8 billion in 2025 and is projected to grow from US$3 billion in 2026 to US$4.8 billion by 2033, at a CAGR of 7.1% from 2026 to 2033. North America held the largest revenue share of 41.9% in 2025.
The growth of the PFAS treatment market is being strongly driven by the growing implementation of stringent environmental regulations and water quality standards across developed and emerging economies, the report said.

"The PFAS water treatment market is witnessing increased adoption across municipal drinking water systems, industrial wastewater treatment facilities, and environmental remediation projects, creating new avenues for technology innovation and market expansion," the research firm said. "Growing investments in industrial wastewater treatment, environmental remediation programs, and ESG-focused sustainability initiatives are also supporting market expansion. Furthermore, rapid urbanization and increasing water quality concerns across Asia Pacific, the Middle East, and Latin America are expected to create substantial long-term opportunities for technology providers and engineering service companies."
The global wound care market is expected to expand from US$22.22 billion in 2025 to US$30.48 billion by 2030, representing a 6.5% compound annual growth rate (CAGR), according to MarketsandMarkets. The report attributed the market's growth to rising rates of chronic diseases, traumatic injuries, burns, and the healthcare demands of an aging population. As healthcare providers, insurers, and manufacturers work to improve patient outcomes while managing long-term costs, wound care has become an increasingly important focus across hospitals, clinics, home healthcare, and long-term care facilities.

The report said demand for wound care products continues to climb as cases of chronic wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, surgical wounds, and trauma-related injuries increase. It notes that delayed wound healing can lead to higher hospitalization costs, greater use of healthcare resources, and increased readmissions, making effective wound management not only a clinical concern but also a financial and operational priority for healthcare organizations.

Ownership and Share Structure
About 14.07% of BioLargo is owned by insiders and management. About 0.04% is held by institutions with 13F-disclosed institutional holdings only. The rest, 85.89%, is retail.
Its market cap is US$33.37 million, with about 320.88 million shares outstanding. It trades in a 52-week range of US$0.10 and US$0.23.

Common Investor Questions
 
What is the AEC, and what has it achieved at Lake Stockholm? The Aqueous Electrostatic Concentrator is BioLargo's proprietary PFAS-removal technology. At Lake Stockholm it has consistently reduced PFAS concentrations in the drinking water to levels below all applicable New Jersey Department of Environmental Protection (NJDEP) standards and U.S. EPA maximum contaminant limits. The underlying press release notes the system removes more than 99% of PFAS. Both the NJDEP and U.S. EPA continue to oversee the system through a 12-month monitoring program to verify it consistently meets or exceeds regulatory standards.

How does the AEC compare with conventional PFAS treatment?
BioLargo says conventional methods such as granular activated carbon and ion exchange often struggle to capture short-chain PFAS, require ongoing replacement of filter media, and generate significant volumes of contaminated spent media and brine requiring hazardous-waste disposal. By contrast, the AEC eliminates the need for granular activated carbon or single-use ion exchange resins and produces only a small volume of concentrated residual waste. At Lake Stockholm, the company says the system has lowered operating costs versus conventional granular activated carbon treatment.

What are PFAS "forever chemicals," and why do they matter?
PFAS (per- and polyfluoroalkyl substances) are built around the carbon-fluorine bond, one of the strongest in organic chemistry, which makes them useful for non-stick and water-resistant products but means they do not break down in the environment or the human body. BioLargo cites research linking PFAS exposure to certain cancers, weakened immune function, thyroid disorders, and developmental harm in children. The company also cited an August 2024 American Water Works Association estimate that utilities would spend US$385,000 to US$500,000 annually per drinking water entry point to comply with EPA PFAS regulations.

What is the Aquatech partnership?
BioLargo has a memorandum of understanding with global water-treatment company Aquatech. The companies intend to pair the AEC with Aquatech's PFAS treatment and destruction capabilities and extend the combined offering beyond municipal drinking water. CEO Dennis P. Calvert described Lake Stockholm as "the launch pad for our strategy with Aquatech."

As an aging population expands demand in the wound care market, a smaller player is taking on the one of the most established with its "chemistry-on-demand" technology.

Smith & Nephew Plc (SNN:NYSE), one of the world's longest-established medical technology companies, traces its roots to 1856, when Thomas James Smith opened a small pharmacy in England; his nephew, Horatio Nelson Smith, later joined to give the firm its enduring name.

Today it describes itself as "a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue," operating under the "Life Unlimited" banner with distribution across more than 100 countries, according to its website.

The business is organized into three global franchises: Orthopedics, Sports Medicine and ENT (ear, nose, and throat), and Advanced Wound Management. In its most recent full year, Smith & Nephew reported revenue of roughly US$6.16 billion, up 6.1%, with operating profit rising to US$794 million and each of its three business units growing more than 5%.

Advanced Wound Management is a cornerstone of the portfolio and the company divides it into three arms — advanced wound care, advanced wound bioactives, and advanced wound devices targeting chronic and hard-to-heal wounds, surgical sites, burns, and pressure injuries, according to the company.

In 2025, the division delivered 6% underlying revenue growth, led by double-digit growth in advanced wound bioactives.

The franchise is anchored by a stable of well-known brands. Its dressing lines include the ALLEVYN family of foam dressings and DURAFIBER; infection management is served by the silver-based ACTICOAT antimicrobial dressings and the cadexomer-iodine IODOSORB/IODOFLEX range; negative-pressure wound therapy runs through the PICO and RENASYS systems; and the bioactives portfolio features the SANTYL collagenase ointment, REGRANEX gel, the OASIS matrix products, and Grafix placental membrane.

In a May 5 release, Smith & Nephew said it planned to highlight its chronic wound management portfolio at the European Wound Management Association (EWMA) Conference in Bremen, Germany, May 6-8.

The Catalyst: The Healthcare Demands of an Aging Population

The global wound care market is expected to expand from US$22.22 billion in 2025 to US$30.48 billion by 2030, representing a 6.5% compound annual growth rate (CAGR), according to MarketsandMarkets.

The report attributed the market's growth to rising rates of chronic diseases, traumatic injuries, burns, and the healthcare demands of an aging population. As healthcare providers, insurers, and manufacturers work to improve patient outcomes while managing long-term costs, wound care has become an increasingly important focus across hospitals, clinics, home healthcare, and long-term care facilities.

The report said demand for wound care products continues to climb as cases of chronic wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, surgical wounds, and trauma-related injuries increase. It notes that delayed wound healing can lead to higher hospitalization costs, greater use of healthcare resources, and increased readmissions, making effective wound management not only a clinical concern but also a financial and operational priority for healthcare organizations.

MarketsandMarkets added that supportive reimbursement policies and government healthcare programs are improving patient access to treatment, while emerging markets are creating new growth opportunities for manufacturers.

Traumatic injuries are one of the key drivers of market expansion, the report said. Citing industry data, it said road traffic accidents cause about 1.3 million deaths each year, while millions more people sustain nonfatal injuries that require wound treatment. It also notes that an estimated 270 million workplace accidents occur globally each year, further increasing demand for wound care products. According to the report, the growing number of trauma cases is boosting the need for advanced dressings, surgical wound care products, biologics, and wound therapy devices.

The report also highlighted the increasing global prevalence of diabetes as another major factor supporting market growth, noting that diabetic foot ulcers remain among the leading reasons for hospitalization in people with diabetes, sustaining long-term demand for specialized wound care therapies and products.

According to a report for Hospital News on January 2 by David Navazio, the industry has posted steady yearly gains over the past five years, and the United States is expected to account for more than 47% of the global market in 2026.

Despite the U.S. maintaining the largest share of the market, the report says international markets are expanding at an even faster pace. It attributes this trend to population aging, broader access to advanced wound care services, and the worldwide adoption of higher standards for wound treatment.

Advances in technology and product development are reshaping the industry as manufacturers work to meet rising demand, Navazio reported, identifying artificial intelligence as one of the most influential developments expected in 2026. He also noted that AI can improve wound assessment, recommend treatment strategies, monitor healing progress, and help prevent future wounds.

Among emerging product trends, the report predicts dressings and other wound care products made with Manuka honey will gain significant traction in 2026. It says the honey, sourced from New Zealand, is valued for its purity and effectiveness and is making a comeback through FDA-approved dressings and topical treatments. The report also highlighted nutrition as an increasingly important component of wound management, emphasizing that adequate protein intake supports tissue growth, cell regeneration, and repair, helping accelerate the healing process.

But avoiding wounds before they develop offers the greatest benefit for patients and healthcare systems, the article said, citing declining diabetes rates in recent years (which experts attribute to improved screening and prevention efforts) as an example of how disease prevention can reduce the incidence of diabetes-related wounds.

Co. Introducing New Wound Management Innovations

Reinforcing its long-term focus on chronic wound care, Smith & Nephew is introducing two new wound management innovations at EWMA in Bremen, both aimed at improving patient outcomes, simplifying treatment, and reducing the demands placed on healthcare professionals. Smith & Nephew said the launch addresses a growing healthcare challenge affecting as many as 14.9 million people across Europe while accounting for up to 4% of healthcare spending.

The company said the new products are designed to support clinicians and patients throughout the continuum of care by improving clinical outcomes and helping patients return to their daily lives.

The new ALLEVYN COMPLETE CARE Foam Dressing features a five-layer construction with specialized mechanisms intended to support wound management while helping prevent pressure ulcers. Smith & Nephew said its enhanced ExuLOCK Technology helps retain exudate and bacteria and releases up to 100 times fewer bacteria than competing foam dressings. The dressing also incorporates the ExuMASK Change Indicator, which helps reduce strikethrough, increases confidence during wound healing, and has been shown to extend wear time compared with other foam dressings. In addition, the ShearDEFENSE Unbonded Layer Technology is engineered to reduce shear forces that can contribute to pressure injuries.

Smith & Nephew said it is also launching the RENASYS EDGE Negative Pressure Wound Therapy System, which emphasizes ease of use while maintaining clinical effectiveness. The lightweight, portable pump is designed to offer intuitive operation and greater discretion for patients while improving convenience. The company said the system significantly enhances wound healing outcomes and achieves an average patient compliance rate of 88% during therapy sessions. Its modular design eliminates the need for annual servicing through low-cost maintenance functionality and supports patient self-care.

"With chronic wound management a strategic priority, we are excited to launch ALLEVYN COMPLETE CARE Dressing and RENASYS EDGE System at EWMA," said Smith & Nephew President of Advanced Wound Management Rohit Kashyap. "Our ongoing commitment to innovation and collaboration continues to drive progress in patient outcomes, as we shape the future of advanced wound care."

Stock Titan on July 27 noted that Cevian Capital II GP Ltd. has disclosed that it beneficially owns 119,179,419 ordinary shares of Smith & Nephew plc, representing a 14.18% stake in the medical technology company based on shares outstanding as of July 23. The filing states that Cevian has sole authority to vote and dispose of all of those shares.

According to the filing, the Cevian Funds acquired the shares for a combined purchase price of approximately US$1,673,390,427, using general working capital to finance the investment.

According to a review of the stock by Simply Wall St. in a piece published by Yahoo! Finance on April 27, Smith & Nephew has delivered strong earnings growth in recent years. Because share prices generally tend to reflect earnings per share (EPS) performance over the long run, sustained EPS expansion is often viewed as an important indicator of corporate health. Over the past three years, the company has posted compound annual EPS growth of 42%, an impressive pace that, while unlikely to continue indefinitely, deserves investors' attention, the article said.

Another measure of the company's performance comes from examining earnings before interest and tax (EBIT) margins alongside revenue growth. Smith & Nephew's EBIT margin remained relatively stable over the past year, while revenue increased 6.1% to US$6.2 billion, a combination that reflects continued top-line expansion.

The analysis also considers whether management's interests are aligned with those of shareholders. With a market capitalization of £9.9 billion, insiders are not expected to own a significant percentage of the company's stock. Even so, insiders collectively hold shares valued at approximately US$12 million, reflecting meaningful financial exposure that may reinforce confidence in the company's strategy. Although that ownership represents only about 0.1% of outstanding shares, it still gives insiders a substantial incentive to pursue initiatives that benefit shareholders.

"Smith & Nephew's earnings per share growth have been climbing higher at an appreciable rate," the article noted. "That sort of growth is nothing short of eye-catching, and the large investment held by insiders should certainly brighten the view of the company. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. Based on the sum of its parts, we definitely think it's worth watching Smith & Nephew very closely. Don't forget that there may still be risks."

Based on recommendations issued by nine Wall Street analysts over the past 12 months, Smith & Nephew has earned a consensus rating of "Hold," according to MarketBeat. Among those analysts, five recommend holding the stock, while the remaining four have assigned it a buy rating, reflecting a generally balanced outlook with a modestly positive tilt toward the shares.

^(1)Less than 1% of the company is held by insiders and management and about 10% is held by institutions. The rest is retail.

Its market cap is US$13.01 billion with 420.26 million shares outstanding. It trades in a 52-week range of US$28.56 and US$38.79.

Clyra Medical Technologies

If Smith & Nephew represents the established scale of the wound care market, Clyra Medical Technologies represents a smaller, focused challenger now testing its edges.

The company is about 48% owned by the publicly traded company BioLargo (BLGO) and is commercializing a wound care platform built around a single patented chemistry: Copper-Iodine Complex Solution, or CICS, marketed as Clyrasept.

Its lead product, ViaCLYR, is an FDA 510(k)-cleared wound irrigation solution indicated for cleansing, irrigating, and debriding dermal wounds and burns and for moistening and lubricating absorbent wound dressings. The clearance covers use on a wide range of wound types — including first- and second-degree burns, Stage I–IV pressure ulcers, diabetic and stasis ulcers, post-surgical wounds, and abrasions.

What distinguishes the technology is a mechanism the company calls "chemistry on demand." Rather than dumping a large, tissue-damaging dose of antiseptic onto a wound all at once, ViaCLYR holds a reservoir of roughly 250 ppm of iodine potential and releases only small amounts of free iodine as pathogens appear, keeping the remainder in reserve for later contamination. According to Clyra's in vitro technical summary, this is what underpins the solution's antimicrobial persistence as a preservative in solution: when researchers re-challenged the solution with fresh doses of bacteria at 10 minutes, 4, 24, 48, and 72 hours without adding any new solution, it continued to neutralize them at every interval, the company said.

The kill data are fast and broad — in laboratory time-kill testing against 19 organisms, essentially all standard bacteria and fungi were neutralized within one minute, including drug-resistant threats such as MRSA, VRE, Acinetobacter baumannii, and the hard-to-kill fungus Candida auris.

The second pillar of Clyra's pitch is safety. Many effective antiseptics are also toxic to the very cells a wound needs to heal, forcing clinicians to choose between killing bacteria and protecting tissue. In comparative cytotoxicity testing, ViaCLYR passed, indicating it does not harm healthy dermal cells. Several standard-of-care agents have failed the same assessment, including Dakin's solution, chlorhexidine gluconate, hydrogen peroxide, and povidone iodine, Clyra said.

These kill-rate and persistence figures come from in vitro laboratory testing and characterize the antimicrobial activity of the solution as a preservative; they are not part of ViaCLYR's FDA clearance, which does not include a claim that the product kills pathogens in the wound or treats or prevents infection.

That combination — potent, resistance-free, broad-spectrum kill without cytotoxicity, and no rinse required — is precisely the gap in the incumbent toolkit that Clyra said it is targeting.

Clyra Chief Executive Officer Steve Harrison illustrated this with a story about a leading burn surgeon whose competitor's product "lasts about two minutes," and whose only fix was more dressing changes.

"More labor, more cost, more time, more pain and suffering to make (the) product work," he told Streetwise Reports. "We're not asking any of that... a product that doesn't need to generate more dressing changes, more suffering, more pain, more crying, more bleeding, and more cost and expense."

The company said it also helps finance-strapped hospitals with its efficiency, which frees up doctors and nurses to treat more patients.

Harrison noted that Clyra is in negotiations with several large U.S. health systems on pricing driven by physician enthusiasm.

Technical Analyst: Clyra Is a Standout Asset for Co.

^(2)On March 11, Technical Analyst John Newell of John Newell & Associates published an in-depth assessment of parent company BioLargo for Streetwise Reports, highlighting the company's progress in the healthcare sector through Clyra.

Newell said BioLargo has pursued a disciplined strategy of developing its proprietary technologies through extensive scientific validation while partnering with established organizations to expand the commercial reach of its innovations. He noted that the company's portfolio spans advanced water treatment, environmental remediation, air quality management, energy storage, and medical technology solutions.

According to Newell, Clyra is one of BioLargo's standout healthcare assets. It uses copper-iodine antimicrobial technologies that remain effective for as long as 72 hours while being non-cytotoxic, making them well-suited for wound care and infection control. He added that Clyra's lead product, ViaCLYR™, has received FDA 510(k) clearance, allowing it to be marketed through established medical device distribution channels. Newell also noted that the technology is protected by approximately 40 issued and pending patents and is offered in multiple formats, including liquids, powders, hydrogels, and antimicrobial dressings.

Based on the potential of BioLargo's technology platforms, Newell assigned the company a Speculative Buy rating. He praised BioLargo's deliberate commercialization strategy and emphasis on strategic partnerships, saying those efforts position the company to benefit from growing demand for advanced healthcare technologies and sustainable energy storage solutions.

On May 18, Oak Ridge Financial Analyst Richard Ryan described BioLargo's business model as a "hub and spoke format — invent/acquire a product, prototype/prove it out, partner with necessary third parties, and commercialize." Ryan reaffirmed his Buy rating on the shares, stating that BioLargo's strategy of commercializing technologies through its operating subsidiaries helps diversify risk while allowing the company to retain significant ownership positions across multiple businesses serving high-growth markets.

https://preview.redd.it/88ntdzv2zigh1.png?width=898&format=png&auto=webp&s=a4acca88b8ec77a4902f32d4817c2e493e7ea2ea

Common Investor Questions

What is ViaCLYR? ViaCLYR is Clyra Medical Technologies' lead product — an FDA 510(k)-cleared wound irrigation and management solution built on its patented Copper-Iodine Complex Solution (CICS), branded Clyrasept. It's used to clean, irrigate, moisturize, and debride acute and chronic wounds.

How does it work? It uses a dual mechanism: the copper-iodine chemistry neutralizes pathogens in solution, and the physical flushing rinses away the dead microbes and debris. Its "chemistry on demand" design holds a reservoir of iodine potential (~250 ppm) and releases only small amounts of free iodine as pathogens appear, which is the basis for its claim of sustained, 72-hour antimicrobial persistence.

What makes it different from existing wound-care products?
Two things. Persistence — it stays active in the wound for up to 72 hours rather than minutes, reducing the need for repeated dressing changes. And safety — in cytotoxicity testing it did not harm the healthy cells needed for healing, whereas several common antiseptics (Dakin's solution, chlorhexidine, hydrogen peroxide, povidone iodine) failed that same test.

How big is the wound-care market opportunity? The global wound care market is projected to grow from about US$22.22 billion in 2025 to US$30.48 billion by 2030 (6.5% CAGR), driven by aging populations, diabetes, and chronic wounds.

https://www.streetwisereports.com/article/2026/07/29/biotechs-non-cytotoxic-copper-iodine-wound-platform-shows-72-hour-antimicrobial-persistence-in-lab-testing.html

https://preview.redd.it/i9o7dli7zigh1.png?width=1166&format=png&auto=webp&s=4d06c0596e965b1300884e445ebf3771e3520432

https://preview.redd.it/w6rtudm9xcgh1.png?width=1884&format=png&auto=webp&s=3eb1ae5c9c4562bbe81fc0c0bcc9c9113255d825

Hey everyone,

I’m R.L, a fellow cinematographer and the Strategic Director of the Cinematography Focus at Evolution Mallorca International Film Festival, and I’d like to personally invite you to be part of what we’re building in Palma this autumn.

In 2026 we celebrate the 15th edition of Evolution Mallorca and the 5th edition of the Cinematography Focus, which we founded in 2022 to put image‑making front and center at the festival. Over those five years the Focus has grown into a dedicated hub for DPs and visual storytellers, with around 1,000 attendees from an international audience, including students, working filmmakers and industry partners.

https://preview.redd.it/lgrkazvvycgh1.jpg?width=1290&format=pjpg&auto=webp&s=64c370a85124be0f7e39d3ae6f1b6f3d9c8bfa98

From 28–30. October in Palma de Mallorca, the Cinematography Focus runs inside the 8‑day festival with:

• Curated masterclasses and hands‑on sessions

• Panel discussions and roundtables

• “Icon Talks” with leading DPs

• Screenings followed by conversations with cinematographers

• Networking lunches, parties and informal meet‑ups

Previous Cinematography Icon Award honorees include Ed Lachman ASC, Erik Messerschmidt ASC, Anthony Dod Mantle ASC BSC DFF and Phedon Papamichael, which gives you an idea of the level of dialogue we’re aiming for.

https://preview.redd.it/zkj2izafxcgh1.png?width=2442&format=png&auto=webp&s=90842801574a93197a8b0b7317a7a9da2ad74654

The festival itself brings more than 8,000 attendees to Mallorca, with 15 years of brand building, extensive press coverage and millions of media impressions, but what I’m most excited about is the creative community that forms around the Focus: people sharing reference frames over coffee, testing new lenses in the gear lounge, and talking about how to build emotion through light and camera movement.

https://preview.redd.it/qqleaqoswcgh1.png?width=1208&format=png&auto=webp&s=304adb5bb415c05860847c02db16da3ee97b11a9

Because this community on r/cinematography has been such a constant source of inspiration and problem‑solving for me, and we want to see the best possible projects I want to extend a special invitation as we approach the final deadline for 2026 submissions. We’ve added dedicated cinematography competition awards:

• Best Cinematography – Short Film

• Best Cinematography – Feature Film

• Best Cinematography – Music Video (new for 2026)

If you have a short, feature or music video where the cinematography is really the heartbeat of the piece, I’d love to see it on the big screen in Palma. For fellow r/cinematography members I’m offering a 50% discount code on submission fees – just reply or DM me and I’ll send it.

It's also ranked as a Top 100 best reviewed Filmfestival on Filmfreeway.

On a personal note, I’m not just involved as a festival VP; I’m also the “+1 in life” of our festival founder and director, Sandra Lipski, and we both care deeply about creating a space where cinematographers feel seen, celebrated and connected.

The Cinematography Focus is our way of weaving your craft into every layer of the festival – from the opening gala and Icon Award to the panels, parties and everyday hallway conversations.

We love to celebrate independent film in style!

I’m happy to answer questions and help you navigate submissions or travel – my goal with this post is simply to introduce the Focus to everyone here and hopefully welcome some of you to Mallorca this October!

New Jersey Institute of Technology and BioLargo Inc. announced that the California-based environmental technology company has joined the New Jersey PFAS Partnership Innovation Consortium, an NJIT-led initiative working to accelerate the development, validation and deployment of solutions addressing per- and polyfluoroalkyl substances, commonly known as PFAS.

BioLargo will contribute its experience developing and commercializing technologies for PFAS detection and treatment, advanced water and wastewater treatment and other environmental challenges. Tonya Chandler, President of BioLargo Equipment, Solutions & Technologies Inc., will also join the NJ PFAS-PIC board of directors.

“We are excited to welcome BioLargo to NJ PFAS-PIC and to add its commercial technology experience to this growing partnership,” said Atam P. Dhawan, NJIT’s chief strategic innovation officer and senior vice provost for research, and executive director of NJ PFAS-PIC. “Its expertise will strengthen our ability to evaluate promising PFAS solutions, validate them under real-world conditions and advance them toward broader adoption by utilities, industries and communities for greater impact.”

BioLargo Equipment, Solutions & Technologies, a wholly owned subsidiary of BioLargo, develops water-treatment systems and provides engineering and system-integration services. Its PFAS portfolio includes testing services and the Aqueous Electrostatic Concentrator, or AEC, which uses an electrostatic field and a proprietary membrane system to separate and concentrate PFAS from contaminated water.

"I'm honored to join the NJ PFAS-PIC board of directors and help guide a consortium doing such critical work on PFAS research, remediation, and innovation.” Chandler states, “PFAS remediation moves fastest when research, industry, and regulators are working from the same table. Throughout my career I've focused on closing the gap between what the regulations require and what available technology can actually deliver. This becomes so important as we look forward to the future of treating PFAS compounds, especially the short and ultra-short compounds that so many existing treatment methods struggle to address. I look forward to bringing a new perspective, along with what we've learned deploying AEC in the field here in New Jersey, to support the consortium's mission."

Developed by NJIT beginning in 2024 and formally launched in April 2026, NJ PFAS-PIC brings together universities, companies, government agencies, utilities and nonprofit and community organizations. The consortium is administered by NJIT and is structured as an industry-university-government-community ecosystem focused on advancing PFAS technologies from early research through application testing, regulatory validation, scaling, commercialization and community adoption.

Its work encompasses PFAS detection and monitoring, remediation, treatment, destruction and management, as well as the development of alternative materials that could reduce or prevent PFAS contamination in consumer and industrial products.

The consortium’s strategy is organized around three central priorities: accelerating emerging technologies from “ideation to impact”; collecting, quantifying and sharing cross-disciplinary PFAS data, including through the use of artificial intelligence; and connecting scientific and technological innovation with community advocacy and the development of effective policies and regulations.

NJ PFAS-PIC members can collaborate through a multi-track Translational Research Partnership Grant Program. The program is designed to support joint proposals for government and private-sector funding, projects initiated by consortium members to address specific technology or community needs, and competitive early-stage research focused on validating emerging PFAS innovations.

Potential projects may include technology testing and demonstration, field and community validation, data collection and analysis, regulatory compliance studies, workforce development, public education and the scaling of technologies toward licensing or commercialization. The consortium also plans workshops, technology showcases, internships and PFAS-focused education and training programs.

BioLargo joins a multidisciplinary group whose members include New Jersey Institute of Technology, Princeton University, Rutgers University, Stevens Institute of Technology, environmental and engineering companies, water utilities, state agencies and community-focused organizations.

“BioLargo’s participation illustrates the type of collaboration NJ PFAS-PIC was created to support,” Dhawan said. “By combining university research with industrial capabilities, regulatory knowledge, utility experience and community priorities, we can create a stronger pathway for moving effective technologies out of laboratories and into practical use.”

OP

$BLGO PFAS is still the thesis, and the catalyst stack keeps growing.

• Tonya Chandler is teaching PFAS 101 at the Tri-State Seminar.

• BioLargo joined the NJIT-led PFAS Partnership Innovation Consortium to advance PFAS detection and treatment solutions.

• The Aquatech MOU is still pushing AEC commercialization forward.

• Dennis Calvert delivered the keynote at the Royal Norwegian Embassy in Washington, D.C., adding more visibility and credibility to the BioLargo PFAS story.

• Lake Stockholm is already installed and producing real-world data.

Sales are still the endgame, and this is not blockbuster news yet. But credibility matters, and BioLargo looks like it’s building that fast across multiple fronts.

Real tech. Real market. Real momentum.

Step by step.

WATER AND OUR COMMON HERITAGE:

FACING THE CHALLENGE OF FOREVER CHEMICALS

Company leaders join environmental attorneys, academic researchers, and industry innovators in a special issue on forever chemicals and the protection of clean water

The PFAS edition combines scientific, policy, social, and artistic perspectives, including a gallery of artwork inspired by water protection and voices from the next generation, all in support of a single theme: the importance of protecting the clean water supply.

About The Disruptive Quarterly
The Disruptive Quarterly, a publication of 22nd Century by Design Solutions, invites artists, writers, thought leaders, scientists, entrepreneurs, and creators to share work that can change minds, hearts, and industries. 

OP

I just spent a couple of hours reading this magazine. Highly Recommended!

NORWAY MEANS BUSINESS - KEYNOTE ADDRESS

Ambassador Huitfeldt, distinguished guests, friends — thank you. 

And thank you, Norcham and Idar Voldnes and, of course, thank you Norway, for opening this house to look into a problem that doesn’t carry a passport and doesn’t respect a border.

I want to begin with a small confession. I’ve spent a little over twenty years of my life in the innovation business. Which means …I’ve spent a little over twenty years asking a two-word question that has cost me ….and a number of very patient shareholders — a considerable amount of money. The question is: “What.. if?”

My accountant has a different favorite question….. “Why?” even better, ….What were you thinking?

The two of us have had a long and productive marriage.

But here is what twenty years has taught me. Every meaningful thing on the agenda today — every technology, every company, every solution — began as somebody’s slightly inconvenient question, “what if.”

What if we could clean water where the old chemistry said we couldn’t? 

What if “forever” wasn’t actually forever?

Curiosity is the cheapest ingredient in innovation. It’s also the one we quietly skip. We’re trained to admire the answer and ignore the question. But the question is the asset. The “what if” is the seed of everything that comes after it — and most of the time, it shows up disguised as a nuisance. The best ideas almost always sound, at first, a little unreasonable.

Curiosity points you at a problem. Then the unglamorous part begins: the deep dive. You go and study the gap.

Not the crowded market everyone is already fighting over — the gap.

The place where the need is enormous and the solutions are thin. As an innovator, you learn to fall in love with gaps, because a gap is just opportunity that nobody has claimed yet.

For me, the PFAS gap didn’t begin with a spreadsheet or a lab report. It began, of all places, with a movie. Some of you have seen Dark Waters — the story of how a class of “forever chemicals” quietly made its way into the blood of, …essentially, …all of us.

What that film captured — more vividly than any data set I’d ever seen — was the visceral reaction: that moment you realize a contaminant has become this widespread, this permanent, and that someone, somewhere, has to decide to fix it.

These are molecules we engineered to be nearly indestructible — and they did their job a little too well.

They’re in our water, our soil, and …in us. 

We’re the first generation able to measure them down to parts per trillion, which makes us the first generation that has to decide what to do about them. 

My company decided to be one of those “someones.” That is a gap worth a career.

And that brings me to the third word. 

Courage.

Because studying a gap is interesting.

But committing your life, your reputation, and other people’s capital to closing one — that is something else entirely.

Every founder in this room knows a particular piece of geography. We call it the valley of death. It’s the distance between “the technology works in the laboratory” and “the world will actually pay for it.” It is where good ideas go to quietly… not make it.

It’s a crowded valley — full of brilliant technologies that were absolutely right, and absolutely alone. Because a breakthrough with no bridge is just an expensive opinion. Courage gets you to the edge of that valley. It does not, by itself, get you across.

Let me make that personal, because I have lived in that valley.

One of our companies, Clyra Medical, has spent nearly twelve years — and a great deal of precious capital — carrying a breakthrough in infection control and wound healing toward the market. The technology worked… really well. And that, it turned out, was the problem.

Because the objection we heard most often wasn’t “it doesn’t work.” It was: 

“This is too good to be true.” We were effective enough that being effective became suspicious. And clearing that one objection — satisfying even the regulators — cost us an additional three and a half years of work and investment. Three and a half years to overcome the crime of working too well.

But we went the distance and came out stronger and more determined to make change for a greater good. And today Clyra is in early market adoption, launching with global partners and industry leaders finally taking up the cause.

Which brings me to the two questions every innovator in this room will recognize. The first you’ve just heard: “Isn’t this too good to be true?” The second is even better: “And who the heck are you?”

As if real innovation were reserved for the upper echelons of academia, or a handful of super-scientists in lab coats. That’s the myth I most want to retire today. 

Innovation isn’t a credential — it’s a commitment. 

It’s the discipline to ask the “what if,” the patience to do the deep dive into the gap, and the courage to go the distance when everyone — including the regulator — is telling you to stop. That’s the whole secret. There isn’t a second one.

But here’s the lesson that took me twenty years to learn: courage gets you across the valley — partnership is what lets you scale on the other side.

With PFAS, we made a deliberate choice early on. 

Not just to build a technology that works — but to build a strategy around it: strategic partnerships that let a proven solution scale at a global pace. Because political winds ebb and flow, budgets tighten, administrations change — but the need for a better solution only gets clearer.

And that strategy is why we now get to watch a technology once waved off as “too good to be true” being adopted around the world and scaling at the highest level — with partners standing alongside us.

Just recently we formed a strategic alliance with Aquatech — and it’s a textbook case of what I mean. Two organizations, different strengths, but mutual incentives that line up perfectly to go after the same gap. Because a problem of this scale isn’t solved by a lone hero in a garage. It takes an army of committed innovators and scaled partners to do it right. And happily — you’ll hear from one of those partners in just a moment: Aquatech’s CEO, Devesh Mittal, is right here on this panel.

So partnership at that scale isn’t just a company strategy. It’s a national one. Which is the reason we’re standing in this particular building today.

I have the privilege of serving on a U.S. federal environmental technology trade advisory committee, where we argue — politely… mostly — that the job of good policy is to shift from punishing what’s dirty to enabling what’s better.

From compliance to enablement. 

Easy to write in a memo. Very hard to do. (I should mention at this moment that all my comments are my own and I am not authorized to speak on behalf of the Secretary of Commerce or the US Government.)

And then I look at Norway, and I realize they’ve quietly been doing the very thing the rest of us keep writing memos about. Norwegians are far too modest to brag about it — so allow an American to do it for them.

Norway didn’t subsidize the world’s largest fleet of electric ferries into existence. It bought them into existence — it used its own purchasing power as an innovation engine. When the government agreed to be the first customer, the valley of death suddenly had a bridge. And its agencies don’t just fund the science; they help underwrite the terrifying middle — the first full-scale deployment private capital is too sensible to finance alone — and, unlike most of us, they actually coordinate with one another.

And then there’s the remarkable project. Norway built the world’s first full-scale system to capture carbon dioxide and lock it permanently beneath the seabed. The government covered roughly two–thirds of the cost, and it began storing carbon just last year. Do you know what they named it?…

Longship. … Of course they did. Because a thousand years ago, Norwegians climbed into open wooden boats and rowed toward a horizon they had no way of seeing. The boat, I’ll grant you,…. has gotten considerably more expensive. But the instinct is exactly the same: point yourself at the unknown — and commit.

So here is the whole arc, in four words.

Curiosity, to ask the question.

Rigor, to study the gap.

Courage, to commit when no one can promise you it will work.

And partnership — the infrastructure, the policy, the patient public WILL — to build a bridge across the valley so the courageous don’t have to cross it alone.

Which is exactly why we’re here this afternoon. The technologies you’re about to hear about on this next panel are not science projects. They’re real, working solutions to PFAS — built by people who asked “what if,” studied the gap, and found the courage to commit. What they need from the rest of us — policymakers, partners, capital — is the bridge.

So here’s the one thing I’d ask you to carry out of this beautiful room. Innovation doesn’t fail in the laboratory. It fails in the gap — between a technology that works and a market that’s ready.

Closing that gap is not an accident. It’s a choice. And it’s a choice every single person in this room has some power to make.

It’s my honor to introduce a group of people who have made that choice — and the solutions they’ve built.

And, a very special thank you to Dr. Cynthia Phillips of 22nd Century by Design for creating this awesome event and making this day a reality!

“If there’s one lesson I carry, it’s this: keep returning to the question, then commit to the bridge. Curiosity, rigor, courage—and partnership. Thank you—over to the panel.

DENNIS P. CALVERT
CEO & CHAIRMAN, BIOLARGO

>Dennis P. Calvert is BioLargo’s President, Chief Executive Officer and Chairman of the Board, and is chairman of the board of directors of each of ONM Environmental and Clyra Medical Technologies, both BioLargo subsidiaries. Mr. Calvert holds a B.A. degree in Economics from Wake Forest University where he was a varsity basketball player, and he also studied at Columbia University and Harding University. He serves on the Board of Sustain SoCal, a trade association that seeks to promote economic growth and stimulate innovation in the Southern California clean technology industry. He also serves on the Board of Directors at TMA BlueTech, the leading regional water cluster promoting science-based ocean and water industries and also serves on the Board of Directors of the Maximum Impact Foundation, a non-profit organization committed to bridging the gap for lifesaving work around the globe for the good of man and in the name of Christ.

More Infos about the Summit and BioLargo:

https://thedisruptivequarterly.com

by Tonya Chandler

PFAS READINESS AND THE OPPORTUNITY FOR AMERICAN MANUFACTURING LEADERSHIP

America deserves a strong manufacturing base and a healthy environment.

For too long, the public conversation has treated environmental stewardship and American manufacturing as if they sit on opposite sides of a scale where one must go down for the other to rise. That oversimplified framing is outdated, and it has kept us stuck in arguments that slow real progress.

Let’s start with some good news.

There is a real sense of momentum in American manufacturing today, and it’s hard not to feel encouraged by it. Communities that spent years watching factories close are now seeing new facilities break ground. Supply chains that proved fragile during the pandemic are now being rebuilt with intention. Critical materials are being produced closer to home again.

Alongside all of that, we’re seeing a surge of real innovation with the development of new processes, new technologies, and new ways of thinking about what responsible industry can look like in the United States.

For anyone who cares about resilient local economies, this is good news. And for those who care about environmental protection, it should be as well.

Time To Reframe the Debate: Manufacturing and Environmental Protection as Shared Goals

Some say we must decide between a strong economy or a healthy environment. That is a common misperception. A progress or ecology debate is outmoded thinking.  Here’s why.

A strong manufacturing base and a healthy environment don’t have to be competing priorities. What was once treated as a tradeoff is now a shared goal: building manufacturing while improving environmental outcomes.

The question isn’t whether we are going to build more data centers, expand chip manufacturing, or strengthen our energy infrastructure. We already are, and these sectors are accelerating globally. They provide the backbone of modern life, showing up in everything from the appliances running in our homes to the systems that protect national security. They drive medical innovation and power the digital tools Americans rely on every day.

The real question is how we do it. 

Embedding environmental stewardship should be a core strategy, not an afterthought. Even as regulation works to catch up, innovation, smarter design, and better technology are making it possible to grow these industries while improving environmental outcomes.

Overcoming the peril of PFAS is central to that challenge. If we are serious about responsible, forward‑looking growth, we have to address one of the most immediate and consequential issues: a class of invisible chemicals most Americans have only recently become aware of, per‑ and polyfluoroalkyl substances, more commonly known as PFAS.

The PFAS Reality Check

Dubbed by the media as “forever chemicals,” PFAS are everywhere. They are found in firefighting foams, personal products, nonstick coatings, industrial finishes, and countless specialty applications tied to manufacturing. They are also extraordinarily persistent. They do not break down, they accumulate in water and soil, and they remain in the human body. The science is still evolving, but what we know today is enough to justify the regulatory response now underway across the country.

As manufacturing scales back up, PFAS is not a side issue. It is a central operational and financial risk. Facilities that use, produce, or discharge PFAS-containing wastewater now face a tightening regulatory landscape: CERCLA designations that trigger long‑term cleanup liability, RCRA rules governing PFAS‑laden waste, and new EPA drinking water standards that force utilities (and the industries that discharge into them) to pay close attention to what’s actually in their water.

This reflects a long‑overdue correction. For decades, industry benefited from PFAS while the public absorbed the environmental cost. Today’s regulatory shift is about rebalancing that equation and if done well, it creates a more predictable, stable operating environment for manufacturers rather than exposing them to the slow‑moving catastrophe of contamination liability.

NPDES Permitting: A New Era of Accountability

For manufacturers that discharge wastewater, the NPDES permit is no longer a routine compliance checkbox. Regulators are increasingly incorporating PFAS monitoring and effluent limits into permits, and companies that wait will find themselves retrofitting systems under pressure. That tends to be expensive, disruptive, and visible.

Companies that engage early, come prepared with data, and demonstrate credible source control generally secure more workable permit conditions and build stronger relationships with regulators.

There’s also the downstream reality: municipal wastewater plants were never designed to remove PFAS. When industry sends PFAS to a municipality, it doesn’t disappear. It moves into effluent, biosolids, and ultimately into downstream discharge, where it can make its way into drinking water.  Municipalities are increasingly unwilling to absorb that burden, and many are already imposing surcharges, flow restrictions, or outright refusals to accept high‑PFAS laden wastewater. Source control and pretreatment aren’t just environmentally responsible, they’re economically rational.

Solid Waste and Landfills: The Hidden PFAS Liability

Solid waste is no different. Are we just kicking the problem down the road? Waste that ends up in a landfill is not a final destination. It is a transfer of responsibility. As PFAS scrutiny intensifies, landfills are facing their own regulatory reckoning, with leachate monitoring, pretreatment mandates, and disposal restrictions tightening nationwide. Manufacturers that rely on landfilling PFAS‑bearing solids, spent media, sludges, filters, wipes, residuals from cleanup, etc. are discovering that what once felt like a low‑visibility option now carries real financial and legal exposure. Landfills are increasingly unwilling to accept high‑PFAS waste without surcharges, special handling fees, or outright rejection, and many are pushing those costs back upstream to the generators. For manufacturers, the smartest path forward mirrors the NPDES landscape: reduce PFAS at the source, minimize the creation of PFAS‑laden solids, and avoid triggering RCRA or CERCLA designations that can follow a company for decades. When facilities invest in treatment approaches that concentrate less waste, generate non‑hazardous solids, or eliminate PFAS altogether, they not only protect the environment, they protect their balance sheets and their community relationships.

What Actually Works: A Toolkit Built on Expertise, Not Silver Bullets

The encouraging news is that we are no longer operating in a technological vacuum. Effective PFAS treatment approaches exist, and the field is advancing quickly. But one of the clearest lessons from real‑world industrial applications is that no single technology solves the PFAS problem on its own. The real differentiator is the expertise required to design a system that fits the chemistry, the flow, the operational realities, and the long‑term liability profile of a specific facility.

A modern PFAS strategy starts with understanding the facility’s own processes; where PFAS originates, how it concentrates, and how it moves through the plant all play a role in creating effective mitigation and treatment. That level of characterization is what allows engineers to design treatment architectures that combine separation, concentration, polishing, and, increasingly, destruction in ways that actually work. The goal is not to pick a technology off the shelf. It is to build a system that fits the facility.

This systems-level approach also creates a pathway to the future. Destruction technologies are maturing quickly, and facilities that design flexible treatment trains today will be able to incorporate those methods as they become commercially viable. In other words, the smartest PFAS strategies are not built around a single piece of equipment, they are built around adaptability, operational simplicity, and a clear understanding of how to keep both environmental and financial risk low over the long term.

The Real Cost Question: Who Pays If Industry Doesn’t?

Opponents of PFAS regulation often frame the issue as a choice between environmental protection and affordable manufacturing. But the costs don’t disappear when industry avoids treatment, they shift to municipalities, to ratepayers, to taxpayers, and to communities.

A manufacturer that invests in pretreatment isn’t just doing the right thing. They’re choosing not to externalize their costs onto the public. And the math is clear: CERCLA cleanups routinely reach tens of millions of dollars, while municipal upgrades triggered by industrial PFAS loading become long‑term financial burdens that are nearly impossible to unwind. 

A Manufacturing Renaissance Worth Celebrating

America needs manufacturing for jobs, resilience, and national security. We can achieve that without repeating the environmental mistakes of the last industrial cycle.

That requires treating PFAS stewardship as a design parameter, not a burden. Facilities that take this approach will see more predictable permit outcomes, lower long-term liability, and more stable operations.

The companies best positioned to succeed will not be the ones resisting environmental responsibility. They will be the ones that recognize a clean operating environment as a competitive advantage. Communities want industry they can trust, municipalities want partners who don’t create unmanageable problems, and regulators work more constructively with facilities that demonstrate genuine commitment.

Rebuilding American manufacturing is worth doing. The question is whether we do it well.

TONYA CHANDLER

Tonya Chandler is President of BioLargo Equipment Solutions and Technologies and a leading voice in PFAS management and industrial water strategy. She works closely with both manufacturers and municipalities to navigate the complex regulatory and operational challenges of PFAS, advancing practical solutions centered on source control, pretreatment, and system design to reduce long-term liability and environmental impact.

Often referred to as “the PFAS lady,” she is also an active advocate for PFAS education, helping industry leaders, regulators, and communities better understand risks, regulations, and the path forward.

from Disruptive Quarterly.

Interesting to hear Barbera’s perspective here, but the bigger question is why the main competition still ends up with only one female director out of 20 films. That imbalance feels hard to ignore, especially when other Venice sections show much stronger representation.